Category Added in a WPeMatico Campaign
MONTREAL--(BUSINESS WIRE)--Lomiko Metals Inc. (TSX.V: LMR) (“Lomiko Metals†or the “Companyâ€) reflects on the news regarding China's announcements to limit...
Releases AI in Education Report, revealing 93% don’t know where to start with AI Unveils the world’s first range of...
SEOUL, South Korea--(BUSINESS WIRE)--ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 1a solid tumour clinical trial (IMC-002-K102...
OMER, Israel, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: SCTC), a leading provider of visual based predictive maintenance...
TORONTO--(BUSINESS WIRE)--$MIMZF #esg--Nighthawk Gold Corp. (“Nighthawk†or the “Companyâ€) (TSX: NHK; OTCQX: MIMZF) delivers its Inaugural Environmental, Social, and Governance...
More than 400,000 merchants in Sri Lanka will be able to accept cross-border digital payments from some of Asia’s most...
TOYOTA, Japan--(BUSINESS WIRE)--#FlyingCars--SkyDrive Inc. (“SkyDriveâ€), a leading Japanese eVTOL aircraft (*1) manufacturer based in Japan, is pleased to announce that...
WUHAN, China--(BUSINESS WIRE)--Customer-oriented, in response to the dominance of road transport in many regions around the world, Dongfeng Commercial Vehicles...
HighField CEO Yuhong Xu and CBO Donald Wyatt are attending BIO-Europe, November 6 – 8, 2023 to discuss these significant...
First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting erythropoietin (EPO) for the treatment...
In a renewed partnership, SES’s hybrid distribution network to enable the NFL to reach over 35 partners in Europe, Asia...
On October 23rd, at the EGM of shareholders, the merger agreement between Celltrion, Inc. & Celltrion Healthcare Co., Ltd. was...
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO:6594) (OTC US:NJDCY) today announced its consolidated financial results under the International Financial Reporting Standards (“IFRSâ€)...
KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (TOKYO: 6594; OTC US: NJDCY) (the “Companyâ€) today announced differences between its financial forecast for the...
Approval based on DESTINY-Lung02 trial results where Daiichi Sankyo and AstraZeneca’s ENHERTU demonstrated a confirmed objective response rate of 49.0%...
